CBIQ
SIGMA/C6617 - ≥98% (HPLC), solid
Synonym: 4-
CAS Number: 32081-28-0
Empirical Formula (Hill Notation): C13H8NCl
Molecular Weight: 213.66
MDL Number: MFCD02179769
Linear Formula: C13H8NCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | off-white |
| form | solid |
| InChI | 1S/C13H8ClN/c14-13-12-6-5 |
| InChI key | SHQLTRRYZVBEMR-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | Clc1nccc2c1ccc3ccccc23 |
| solubility | DMSO: 15 mg/mL |
| Biochem/physiol Actions: | CBIQ is a cystic fibrosis transmembrane conductance regulator (CFTR) activator; intermediate-conductance calcium-sensitive K+ channel (KCNN4) activator. |
| Biochem/physiol Actions: | CBIQ is an activator of the cystic fibrosis transmembrane conductance regulator (CFTR) and the intermediate-conductance calcium-sensitive K+ channel (KCNN4). CBIQ is a novel tool for a new ion channel; first activator of ΔF508 CFTR, the mutant form of CFTR chloride channel present in 75% of cystic fibrosis patients. Other benzoquinolines act at the normal CFTR but not at ΔF508 CFTR. CBIQ also activates KCNN4, which hyperpolarizes airway epithelial cells to promote anion flux, a further benefit in cystic fibrosis. |
| Features and Benefits: | This compound is featured on the Chloride Channels and Potassium Channels pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | ![]() GHS05,GHS06 |
| Signal word | Danger |
| Hazard statements | H301 - H315 - H318 - H335 |
| Precautionary statements | P280 - P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338 + P310 |
| Hazard Codes | T |
| Risk Statements | 25-37/38-41 |
| Safety Statements | 26-39-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |



